Ter opwarming voor Q2, zomaar een aantal uitspraken van Jan Groen:
Medicare reimbursement has been implemented for all three of these assays, which is a significant achievement within the diagnostic industry
Medicare coverage for ConfirmMDx for Prostate Cancer became effective with a reimbursement price of $2,030 per patient test. This is expected to have a material impact on continued market adoption and product revenues.
Medicare coverage for ConfirmMDx for Prostate Cancer is a significant achievement for the company and we are committed to taking all the steps necessary to ensure continued and expanded availability to men suspected of harboring prostate cancer,
The increased adoption of ConfirmMDx for Prostate Cancer within the U.S. urology community, together with two other commercialized cancer tests based on our proprietary technology, has established MDxHealth as a market leader in the important and growing field of cancer epigenetics.
For fiscal year 2015, the Company expects continuing growth in ConfirmMDx test volume and revenue driven by the recent positive Medicare coverage decision
The Company expects to transition more payors to an accrual accounting basis resulting in increased revenue recognition in 2015
I am very pleased by the performance of our entire commercial team at MDxHealth, especially given the strong results delivered this quarter despite the industry-wide impact caused by severe winter weather conditions in the northeastern US in Q1 2015.
We are delighted to have raised this additional funding from a mix of new investors who share our belief in the commercial potential of our world leading DNA methylation platform
Philip is a valuable addition to the MDxHealth team; with an excellent pedigree in the diagnostics and urology sectors and an entrepreneurial approach, we are confident he will immediately contribute to our on-going growth and success
Q2 vertellen dat het allemaal niet zo is valt in de categorie Imtech, maar goed, daar gaan ze zeer aannemelijk achter slot en grendel.